Mitochondrial Myopathy Diagnosis & Treatment Market research Report - Global Forecast till 2025

Report / Search Code: MRFR/Pharma/2648-CR  Publish Date: July, 2019

Request Sample

Price 1-user PDF : $ 4450.0  Enterprise PDF : $ 6250.0

Description:

Global Mitochondrial Myopathy Diagnosis & Treatment Market Research Report:
Information by Type (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes, Progressive External Ophthalmoplegia, Myoclonic Epilepsy with Ragged Red Fibers, Mitochondrial Neurogastrointestinal Encephalopathy Syndrome, Kearns–Sayre Syndrome (KSS), Mitochondrial DNA Depletion Syndrome, Pearson Syndrome, Leigh Syndrome, Neuropathy, Ataxia and others), Diagnostic Test (Genetic Tests, Muscle Biopsy and Biochemical Test), Deployment Models (On-Premise and Cloud-Based), Therapy (Supportive Therapy and Targeted Therapy) and Region - Forecast Till 2025

Market Scenario

The Global Mitochondrial Myopathy Diagnosis & Treatment Market is growing at a healthy pace and is expected to be USD 20.4 million in 2016, at a CAGR of 9.8% during the forecast period 2017-2025.

The mitochondrial myopathy treatment provides relief from mitochondrial myopathies such as Barth syndrome, chronic progressive external ophthalmoplegia (CPEO), Kearns-Sayre syndrome (KSS), etc. There exists no cure for the mitochondrial myopathy, although many drugs are in the pipeline, and few have received fast track approval and orphan drug status. The factors such as rising number of screening services for mitochondrial disorders, a growing number of mitochondrial myopathy cases, increased government funding, and incentives for rare genetic diseases are driving the market for mitochondrial myopathy diagnosis & treatment. However, inadequate treatment options and the absence of curative treatment have constrained the market. The treatment options have been divided into curative and symptomatic management of conditions associated with mitochondrial myopathies such as stroke and cardiac symptoms.

Market Dynamics

Mitochondrial myopathy is a rare mutational disease, and at present, there is no concrete treatment available for the disease. However, there are few diagnostic tests available in the market, which are the only saving grace for the global mitochondrial myopathy diagnosis and treatment market at present. There are certain factors which drive the growth of the market. These include a rise in the number of mitochondrial myopathy patients, development in the disease screening process and testing services, lucrative incentives for the rare genetic diseases, and government funding and support for the development of the treatment options.

Further, rising number of screening and a growing number of mitochondrial myopathy cases for example, in the US, new-born screening is performed on every infant regardless of the parent’s health insurance status or paying ability with some states not even charging the nominal fees for the testing. Any other expenses are covered by most private health insurance plans and the Children’s Health Insurance Program (CHIP) and Medicaid both cover the cost. Thus, rising screening both due to government regulations and increasing insurance penetration is estimated to drive the future growth of mitochondrial myopathies treatment market.

On the other hand, poor treatment options and unavailability of the curative treatment for the mitochondrial myopathy, lack of awareness, and a high number of the underdiagnosed population are some of the factors which hinder the growth of the mitochondrial myopathy diagnosis &
Segmentation

The global mitochondrial myopathy diagnosis & treatment market has been segmented based on type, services, diagnostic test, therapy. On the basis the type, the market has been segregated into mitochondrial, encephalomyopathy, lactic acidosis, and stroke-like episodes, progressive external ophthalmoplegia, myoclonic epilepsy with ragged red fibres, mitochondrial neurogastrointestinal encephalopathy syndrome, Kearns–Sayre syndrome, mitochondrial DNA depletion syndrome, Pearson syndrome, Leigh syndrome, neuropathy, ataxia, and retinitis pigmentosa. On the basis of diagnostic tests, the market has been bifurcated into genetic tests, muscle biopsy, biochemical test. Based on therapy, the market has been divided into supportive therapy and targeted therapy.

Regional Analysis

The global market for mitochondrial myopathy diagnosis & treatment has been segmented on the basis of regions into the Americas, Europe, Asia-Pacific, and Middle East & Africa. Among these has captured the whole market of mitochondrial myopathy at present as there are no targeted therapies available in the market. There are few molecules under clinical development for the targeted treatment of the mitochondrial myopathy, which is expected to be available in the market after 2021. However, supportive therapy will continue to dominate the global market until the availability of concrete treatment for the disease.

Americas mitochondrial myopathy market is the largest market for the diagnosis and treatment of mitochondrial myopathy. Advanced healthcare services, state of the art healthcare infrastructure, availability of the better healthcare services and outcomes, development in the genetic testing spectrum, high awareness about the mitochondrial diseases among the population, efforts taken by various organization for spreading the awareness about such rare disease conditions. All these factors culminate to make the American region the largest market in the world. Some of the companies such as GeneDx and ARUP laboratories, among others are involved in the genetic testing of the mitochondrial diseases, including myopathy. Moreover, few companies such as Stealth Biotherapeutics are engaged in the development of the novel drugs for the targeted therapies for the mitochondrial myopathies.

- **July 2017** Centogene AG signed a cooperation agreement with University Hospital St. Ivan Rilski in Bulgaria. The collaboration helped the company in expanding its genetic testing portfolio.

- **June 2017** Centogene AG raised nearly Euro 25 million in the financial round led by the TVM Capital Life Science in cooperation with DPE Deutsche Private Equity, Careventures, and CIC Capital. The financial boost enabled the company to provide a more extensive genetic
testing portfolio to a larger customer base.

Market Segmentation and Key Market Players

Global Mitochondrial Myopathy Diagnosis & Treatment, by Type
- Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes
- Progressive External Ophthalmoplegia
- Myoclonic Epilepsy with Ragged Red Fibers
- Mitochondrial Neurogastrointestinal Encephalopathy Syndrome
- Kearns–Sayre Syndrome
- Mitochondrial DNA Depletion Syndrome
- Pearson Syndrome
- Leigh Syndrome
- Neuropathy, Ataxia, and Retinitis Pigmentosa

Global Mitochondrial Myopathy Diagnosis & Treatment, by Diagnostic Test
- Genetic Tests
- Muscle Biopsy
- Biochemical Test

Global Mitochondrial Myopathy Diagnosis & Treatment, by Therapy
- Supportive Therapy
- Targeted Therapy

Global Mitochondrial Myopathy Diagnosis & Treatment, by Key Players
- AbbVie Inc.
- Centogene AG
- GeneDx
- Ixchel Pharma
- Khondrion BV
- Mitobridge
- NeuroVive Pharmaceutical AB
- Reata Pharmaceuticals Inc.
- Stealth Biotherapeutics

Intended Audience
- Biotechnology companies
- Hospitals
- Research and development (R&D) companies
- Market research and consulting service providers
- Potential investors

Contents:

<table>
<thead>
<tr>
<th>License</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single User</td>
</tr>
</tbody>
</table>

TABLE OF CONTENTS

1 INTRODUCTION
1.1 Definition 9
1.2 Scope of Study 9
1.3 Research Objective 9
1.4 Assumptions & Limitations 10
1.4.1 Assumptions 10